OpenLB
Open Library of Bioscience
Advanced Search
Scientific reports
10 18, 2024;14 (1): 24480.

Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task.

Amit Olami, Leehe Peled-Avron
Author Information
  1. Amit Olami: Department of Psychology, Bar Ilan University, Ramat-Gan, Israel. amitol1222@gmail.com.
  2. Leehe Peled-Avron: Department of Psychology, Bar Ilan University, Ramat-Gan, Israel. leehe.peled@biu.ac.il.
PMID: 39424835 DOI: 10.1038/s41598-024-74810-w

Abstract

This meta-analysis investigates the effect of classic psychedelic drugs on empathy and focuses on cognitive and emotional empathy measured using the Multifaceted Empathy Test (MET). Empathy entails the ability to understand and share the feelings of another and is a significant component of social interaction. Several studies have examined the effects of psychedelic drugs such as LSD, psilocybin and ayahuasca on empathy, yet their overall effect has not been studied so far. In this meta-analysis, we reviewed data from studies up to November 2023 with the aim of examining the effects of various psychedelic drugs on empathic abilities broadly. Our findings suggest that classical psychedelics significantly enhance explicit and implicit emotional empathy without affecting measures of cognitive empathy. The results emphasize the need to continue testing the therapeutic potential of classic psychedelic drugs.

References

  1. PLoS One. 2017 Feb 10;12(2):e0171665 [PMID: 28187194]
  2. Commun Psychol. 2024 Apr 11;2(1):29 [PMID: 39242813]
  3. Neuroreport. 1998 Dec 1;9(17):3897-902 [PMID: 9875725]
  4. Soc Cogn Affect Neurosci. 2017 Oct 1;12(10):1545-1557 [PMID: 28981910]
  5. Front Psychol. 2021 Nov 24;12:781346 [PMID: 34899531]
  6. J Child Psychol Psychiatry. 2001 Feb;42(2):241-51 [PMID: 11280420]
  7. Neuropsychopharmacology. 2016 Oct;41(11):2638-46 [PMID: 27249781]
  8. Cogn Affect Behav Neurosci. 2016 Oct;16(5):802-13 [PMID: 27165338]
  9. J Psychoactive Drugs. 2019 Apr-Jun;51(2):123-134 [PMID: 30905276]
  10. Pharmacol Rev. 2016 Apr;68(2):264-355 [PMID: 26841800]
  11. Perspect Psychol Sci. 2020 Mar;15(2):384-396 [PMID: 32069168]
  12. Curr Drug Abuse Rev. 2013 Mar;6(1):30-42 [PMID: 23627784]
  13. Behav Brain Res. 1996;73(1-2):121-4 [PMID: 8788488]
  14. Psychopharmacology (Berl). 2011 Dec;218(4):649-65 [PMID: 21674151]
  15. Dis Nerv Syst. 1961 Aug;22:459-62 [PMID: 13775877]
  16. Brain Res Bull. 2016 Sep;126(Pt 1):89-101 [PMID: 26976063]
  17. Soc Cogn Affect Neurosci. 2014 Nov;9(11):1645-52 [PMID: 24097374]
  18. J Autism Dev Disord. 2008 Mar;38(3):464-73 [PMID: 17990089]
  19. Front Pharmacol. 2021 Jul 13;12:711255 [PMID: 34326773]
  20. Hum Psychopharmacol. 2013 Jul;28(4):289-307 [PMID: 23881877]
  21. J Neurosci. 2013 Sep 18;33(38):15171-83 [PMID: 24048847]
  22. J Autism Dev Disord. 2006 Jul;36(5):623-36 [PMID: 16755332]
  23. Neuropharmacology. 2011 Sep;61(3):364-81 [PMID: 21256140]
  24. Front Pharmacol. 2021 Oct 01;12:721537 [PMID: 34658861]
  25. J Psychopharmacol. 2013 Jan;27(1):40-52 [PMID: 23118021]
  26. Front Hum Neurosci. 2016 Jun 14;10:269 [PMID: 27378878]
  27. J Clin Psychopharmacol. 2021 May-Jun 01;41(3):267-274 [PMID: 33843820]
  28. Drug Alcohol Depend. 2020 Jul 1;212:108071 [PMID: 32450479]
  29. Nat Struct Mol Biol. 2015 May;22(5):362-9 [PMID: 25895059]
  30. BMJ. 2016 Oct 12;355:i4919 [PMID: 27733354]
  31. Front Psychiatry. 2019 Dec 03;10:881 [PMID: 31849730]
  32. Trends Cogn Sci. 2006 Oct;10(10):435-41 [PMID: 16949331]
  33. Neurotherapeutics. 2017 Jul;14(3):734-740 [PMID: 28585222]
  34. BMJ. 1997 Sep 13;315(7109):629-34 [PMID: 9310563]
  35. Syst Rev. 2015 Jan 01;4:1 [PMID: 25554246]
  36. Int J Neuropsychopharmacol. 2018 Apr 1;21(4):333-344 [PMID: 29087534]
  37. Neuroscientist. 2011 Feb;17(1):18-24 [PMID: 21071616]
  38. Neuroimage. 2011 Oct 1;58(3):895-904 [PMID: 21742042]
  39. BMJ. 2019 Aug 28;366:l4898 [PMID: 31462531]
  40. Stat Med. 2009 Jun 30;28(14):1861-81 [PMID: 19399825]
  41. J Psychoactive Drugs. 2021 Apr-Jun;53(2):97-103 [PMID: 33252034]
  42. Rev Neurosci. 2021 Feb 08;32(5):559-571 [PMID: 33550787]
  43. Int J Neuropsychopharmacol. 2017 Sep 1;20(9):747-757 [PMID: 28637246]
  44. Life Sci. 1998;63(3):215-22 [PMID: 9698051]
  45. J Psychopharmacol. 2011 Nov;25(11):1453-61 [PMID: 21956378]
  46. Psychopharmacology (Berl). 2021 Jul;238(7):1899-1910 [PMID: 33694031]
  47. Nat Neurosci. 2012 Apr 15;15(5):675-80 [PMID: 22504346]
  48. Percept Mot Skills. 2007 Apr;104(2):589-98 [PMID: 17566449]
  49. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):263-72 [PMID: 22691716]
  50. Eur Neuropsychopharmacol. 2015 Apr;25(4):483-92 [PMID: 25637267]
  51. Neuron. 2024 Oct 9;112(19):3295-3310.e8 [PMID: 39094559]

MeSH Term

Humans
Cognition
Emotions
Empathy
Hallucinogens
Lysergic Acid Diethylamide
Psilocybin

Chemicals

Hallucinogens
Lysergic Acid Diethylamide
Psilocybin
Journal Article Meta-Analysis
Article has an altmetric score of 6

Word Cloud

Created with Highcharts 10.0.0empathypsychedelicdrugsmeta-analysiscognitiveemotionaleffectclassicEmpathyMETstudieseffectsclassicalpsychedelicsexplicitimplicitinvestigatesfocusesmeasuredusingMultifacetedTestentailsabilityunderstandsharefeelingsanothersignificantcomponentsocialinteractionSeveralexaminedLSDpsilocybinayahuascayetoverallstudiedfarrevieweddataNovember2023aimexaminingvariousempathicabilitiesbroadlyfindingssuggestsignificantlyenhancewithoutaffectingmeasuresresultsemphasizeneedcontinuetestingtherapeuticpotentialEffectsempathy:task

Similar Articles

Cited By